KAND 567

Drug Profile

KAND 567

Alternative Names: AZD-8797; KAN-0440567; KAND567

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Kancera
  • Class Analgesics; Antineoplastics; Small molecules
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer pain; Pancreatic cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 14 Sep 2017 Kancera enters into development and manufacturing agreement with Kancera for KAND 567 in the treatment of Cancer pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top